EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseLeitlinie

Efficacy and safety of dexamethasone sparing for the prevention of nausea and vomiting associated with highly emetogenic risk antineoplastic agents: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023 from the Japan Society of Clinical Oncology

Ayako Yokomizo, Kazuhisa Nakashima, Arisa Iba, Kenji Okita, Makoto Wada, Keiko Iino, Tatsuo Akechi, Hirotoshi Iihara, Chiyo K Imamura, Ayako Okuyama, Keiko Ozawa, Yong-Il Kim und 16 weitere

International Journal of Clinical Oncology · 2024

DOI: 10.1007/s10147-024-02624-x ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift International Journal of Clinical Oncology, 2024. Verfasst von Ayako Yokomizo und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Early Clinical Development, Kyoto University Graduate School of Medicine, 54 Kawaharacho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan. Hauptthemen laut MEDLINE: Antiemetics, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Nausea. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: Japan Society of Clinical Oncology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Chemotherapy-induced nausea and vomiting (CINV) are common side effects, classified according to timing and severity. Conventional agents such as dexamethasone are effective but have various side effects. For moderately emetogenic chemotherapy, dexamethasone-sparing antiemetic therapies have been developed to minimize these side effects. This systematic review evaluated the efficacy and safety of dexamethasone-sparing antiemetic therapy for highly emetogenic chemotherapy (HEC). METHODS: We performed a thorough literature search for studies related to dexamethasone-sparing antiemetic therapy with neurokinin-1 antagonists (NK1RA) for HEC using the PubMed, Cochrane Library, and Ichushi-Web databases. A qualitative analysis of the combined data was performed and risk differences with confidence intervals were calculated. RESULTS: Two reviewers independently assessed the 425 records and 12 full-text articles were evaluated for eligibility. Two studies were included in the qualitative and meta-analyses. These studies included anthracycline-cyclophosphamide (AC) regimens and cisplatin-based regimens, with palonosetron as the serotonin receptor antagonist. In the two studies, no difference was found in the prevention of vomiting (delayed complete response). However, non-inferiority was not demonstrated in the subgroup that received cisplatin-containing regimens. Delayed complete control showed different results for nausea prevention; however, there was no significant difference in the meta-analysis. Only one report has shown non-inferiority for delayed total control. Although the strength of evidence for individual outcomes varied, there was no difference in the duration of dexamethasone administration. CONCLUSIONS: This systematic review and meta-analysis revealed that dexamethasone-sparing antiemetic therapy with NK1RA and palonosetron can be used to prevent CINV in HEC, limited to AC combination therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AntiemeticsAntineoplastic Combined Chemotherapy ProtocolsDexamethasoneNauseaVomitingHumansAntineoplastic AgentsCisplatinJapanNeoplasmsNeurokinin-1 Receptor AntagonistsPalonosetronPractice Guidelines as Topic

Stichwörter der Autor:innen

Chemotherapy-induced nausea and vomitingDexamethasoneHighly emetogenic chemotherapyMeta-analysisSparing

Substanzen

AntiemeticsAntineoplastic AgentsCisplatinDexamethasoneNeurokinin-1 Receptor AntagonistsPalonosetron

Autor:innen und Institutionen

  • Department of Early Clinical Development, Kyoto University Graduate School of Medicine, 54 Kawaharacho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.
  • Faculty of Medicine, Department of Internal Medicine, Division of Medical Oncology & Respiratory Medicine, Shimane University, 89-1 Enya-Cho, Izumo, Shimane, 693-8501, Japan. kazuhin@med.shimane-u.ac.jp.
  • Institute for Global Health Policy Research, Bureau of International Health Cooperation, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku, Tokyo, 162-8655, Japan.
  • Department of Surgery, Otaru Ekisaikai Hospital, 1-4-1, Inaho, Otaru, Hokkaido, 047-0032, Japan.
  • Department of Psycho-Oncology and Palliative Medicine, Osaka International Cancer Institute, Otemae 3-1-69, Chuo-ku, Osaka, 541-8567, Japan.
  • School of Nursing, National College of Nursing School of Nursing, National College of Nursing, Japan, 1-2-1, Umezono, Kiyose, Tokyo, 204-8575, Japan.

Förderung

  • Japan Society of Clinical Oncology

Zitieren

APA

Yokomizo, A., Nakashima, K., Iba, A., Okita, K., Wada, M., Iino, K., Akechi, T., Iihara, H., Imamura, C. K., Okuyama, A., Ozawa, K., Kim, Y. I., Sasaki, H., Satomi, E., Takeda, M., Tanaka, R., Nakajima, T. E., Nakamura, N., Nishimura, J., …, & Abe, M. (2024). Efficacy and safety of dexamethasone sparing for the prevention of nausea and vomiting associated with highly emetogenic risk antineoplastic agents: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023 from the Japan Society of Clinical Oncology. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-024-02624-x

Vancouver

Yokomizo A, Nakashima K, Iba A, Okita K, Wada M, Iino K, et al. Efficacy and safety of dexamethasone sparing for the prevention of nausea and vomiting associated with highly emetogenic risk antineoplastic agents: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023 from the Japan Society of Clinical Oncology. International Journal of Clinical Oncology. 2024. doi:10.1007/s10147-024-02624-x

BibTeX
@article{Yokomizo2024,
  author = {Yokomizo, Ayako and Nakashima, Kazuhisa and Iba, Arisa and Okita, Kenji and Wada, Makoto and Iino, Keiko and Akechi, Tatsuo and Iihara, Hirotoshi and Imamura, Chiyo K and Okuyama, Ayako and Ozawa, Keiko and Kim, Yong-Il and Sasaki, Hidenori and Satomi, Eriko and Takeda, Masayuki and Tanaka, Ryuhei and Nakajima, Takako Eguchi and Nakamura, Naoki and Nishimura, Junichi and Noda, Mayumi and Hayashi, Kazumi and Higashi, Takahiro and Boku, Narikazu and Matsumoto, Koji and Matsumoto, Yoko and Yamamoto, Nobuyuki and Aogi, Kenjiro and Abe, Masakazu},
  title = {Efficacy and safety of dexamethasone sparing for the prevention of nausea and vomiting associated with highly emetogenic risk antineoplastic agents: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023 from the Japan Society of Clinical Oncology},
  journal = {International Journal of Clinical Oncology},
  year = {2024},
  doi = {10.1007/s10147-024-02624-x}
}
Kostenlos starten →